Pressure BioSciences Inc. (OTCMKTS:PBIO) posted its quarterly earnings data on Wednesday. The company reported ($0.54) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.90) by $0.36, MarketWatch Earnings reports.

Pressure BioSciences (OTCMKTS PBIO) traded down 0.91% during mid-day trading on Wednesday, reaching $4.36. The company’s stock had a trading volume of 13,768 shares. The stock’s 50 day moving average is $6.03 and its 200 day moving average is $2.50. The company’s market cap is $4.77 million. Pressure BioSciences has a 12 month low of $3.62 and a 12 month high of $13.50.

COPYRIGHT VIOLATION WARNING: This article was first posted by Watch List News and is owned by of Watch List News. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.watchlistnews.com/pressure-biosciences-inc-pbio-announces-earnings-results-beats-expectations-by-0-33-eps/1494717.html.

Separately, ValuEngine downgraded Pressure BioSciences from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 2nd.

Pressure BioSciences Company Profile

Pressure BioSciences, Inc is focused on solving the problems inherent in biological sample preparation. The Company has developed and patented a technology platform that can control the sample preparation process. This process, called pressure cycling technology (PCT), uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels, such as approximately 35,000 pounds per square inch (psi) or greater to control the actions of molecules in biological samples, such as cells and tissues from human, animal, plant and microbial sources.

Earnings History for Pressure BioSciences (OTCMKTS:PBIO)

Receive News & Ratings for Pressure BioSciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pressure BioSciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.